Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

March 2024

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial

Lancet 2024;403(10429):850–859 doi 10.1016/S0140-6736(23)02650-8

Rech J,

Hagen M,

Braun J,

Kiltz U,

Fleck M,

Voll R,

Thiel J,

Feist E,

Largo R,

This study by Rech, et al. shows that 6-month treatment with abatacept was associated with a decrease in MRI inflammation, clinical symptoms, and risk of RA development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase.

Keywords:

May 2022

Étude rétrospective de l'efficacité des inhibiteurs de JAK ou de l'abatacept sur la polyarthrite rhumatoïde et la pneumopathie interstitielle

Inflammopharmacology. 2022. Epub ahead of print doi: 10.1007/s10787-022-00936-w

This study of the effectiveness of JAKinibs or abatacept in patients with RA-interstitial lung disease (RA-ILD) shows that treatment is related to stability or improvement of RA-ILD in over 80% of patients.

Keywords:

L'impact du tofacitinib sur la fatigue, le sommeil et la qualité de vie liée à la santé chez les patients atteints de polyarthrite rhumatoïde : une analyse post hoc des données des essais de phase 3

Arthritis Res Ther. 2022;24(1):83 doi:10.1186/s13075-022-02724-x

Gold DA,

This was an exploratory post hoc analysis of pooled data, from over 2000 patients in three Phase 3 studies of tofacitinib, which demonstrates an association between tofacitinib treatment and significantly greater improvements in fatigue, sleep, and health-related quality of life (HRQoL), compared with placebo.